Alvotech
Alvotech develops and manufactures biosimilars of high-value biologic therapies, aiming to improve global access to effective biological treatments through more accessible alternatives to brand-name drugs.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – 2 January 2026
Listen to the episodeAbout Alvotech
Alvotech is a biopharmaceutical company founded in 2013 in Reykjavik by Róbert Wessman (founder of Actavis). The company specialises in the development and manufacture of high-quality biosimilars with the aim of improving access to biologic therapies worldwide. Listed on Nasdaq (ALVO), Alvotech is one of Europe's leading players in the biosimilar sector with a diversified pipeline. In early 2026 it secured a €100M term loan to strengthen liquidity and accelerate R&D investment and pipeline development.
Market & Clients
Key Customers
Healthcare systems, insurers and pharmaceutical distributors seeking more accessible biological alternatives.
Geographic Presence
Funding & Investors
Funding Rounds
- 2026 - Term loan: €100M
Similar Startups
Alan
Digital health insurance platform offering transparent, affordable health coverage for individuals and SMEs.
Read AnalysisNewAmsterdam Pharma
Biopharmaceutical company focused on innovative therapies for hypercholesterolemia and cardiometabolic diseases with breakthrough clinical results.
Read AnalysisMindMaze
Swiss startup in digital neurorehabilitation integrating virtual reality, motion tracking and AI to restore motor function after stroke or injury.
Read Analysis